EPA Chemical Board Appointments Signal Deregulation Push
The Trump administration has appointed at least 13 industry-affiliated scientists to an EPA chemical safety panel, signaling a likely shift toward deregulation that could lower compliance costs for manufacturers.
The Environmental Protection Agency has named a new roster of experts to its Science Advisory Committee on Chemicals. Public health advocates allege that at least 13 of the 20 to 23 appointees have direct financial conflicts of interest regarding the toxic substances they are tasked with reviewing.
For the chemical sector, a panel heavily weighted toward industry voices suggests the agency's risk analyses are likely to favor looser standards. This shift could significantly reduce compliance and remediation costs for manufacturers, boosting margins for companies that handle toxic substances.
The financial overlaps are stark in certain cases. Wade Barranco, an employee of Lyondell Chemical Company, was appointed despite his employer releasing nearly 1m pounds of chemicals slated for SACC review in 2024, including benzene and styrene.
Another appointee, Michael Dourson, runs Toxicology Excellence for Risk Assessment, a firm critics characterize as a hub for industry-friendly research. Trump previously nominated Dourson to lead the EPA's chemical safety division in 2017, but he withdrew after failing to secure enough Senate support. A coalition report now states Dourson has been paid by chemical makers to work on substances the SACC will soon evaluate, including acrylonitrile and naphthalene.
These appointments face immediate legal and political friction. Advocates argue they violate federal law requiring the SACC to be free from conflicts, with Erik D Olson of the Natural Resources Defense Council calling the appointees "mouthpieces for the chemical industry." Olson warned that the overlapping interests mean "there won’t be independent voices" in the review process.
The EPA rejected these assertions. The agency stated that prior industry work constitutes "general scientific expertise" rather than a disqualifying conflict under federal law.
While an industry-friendly board may streamline chemical approvals for producers, the concentration of corporate affiliations invites legal challenges from non-profits. Environmental litigation could ultimately stall the deregulatory actions that chemical executives and investors are anticipating, replacing regulatory clarity with prolonged legal battles.
